Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
PCRFY Panasonic Holdings Corp
CRTD Creatd Inc
MSM MSC Industrial Direct Co Inc
FGEN FibroGen Inc
SUI Sun Communities Inc
HROWL HARROW HEALTH 8 625 SNR NTS
COF-I Capital One Financial Corp
VRAY ViewRay Inc
PEBC Peoples Bancorp Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Postmarket

Last Trade
Delayed
$243.85
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$243.85
Day's Change
-1.32 (-0.54%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
246.80
Day's Low
243.45
Volume
(Light)
Volume:
2,165,044

10-day average volume:
2,953,242
2,165,044

Display:

Providers:

UpdateCancel
6 providers
January 26, 2023
AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the...(PR Newswire)

January 06, 2023
AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET

Biotherapeutics Company to Receive lab Space, Mentoring and Other Benefits Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California...(PR Newswire)

January 04, 2023
AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast...(PR Newswire)

December 20, 2022
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen's Phase 3 trial of olpasiran. Arrowhead is further eligible to...(BusinessWire)

December 13, 2022
BLINCYTO(R) (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

At 3.5 Years, 83% of Patients on BLINCYTO Plus Chemotherapy Were Alive Versus 65% of Patients on Chemotherapy Alone Trial Design and Conduct Sponsored by the ECOG-ACRIN Cancer Research Group Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer...(PR Newswire)

December 12, 2022
AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will be paid on March 8, 2023, to all stockholders of record as of the close of business on February 15...(PR Newswire)

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Horizon Therapeutics plc (HZNP)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - December 12, 2022) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Horizon Therapeutics plc ("Horizon Therapeutics" or the...(Newsfile)

SHAREHOLDER ALERT: Weiss Law Investigates Horizon Therapeutics Public Limited Company

Weiss Lawis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company ("Horizon Therapeutics" or the "Company") (NASDAQ: HZNP) in connection with the...(PR Newswire)

AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022. Robert A. Bradway, chairman and chief executive officer, along with...(PR Newswire)

Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION (PR Newswire)

December 01, 2022
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022

AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks Initiating Phase 2 Study in Early 2023 (PR Newswire)

November 28, 2022
AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday, Dec. 5, 2022. David M. Reese, M.D...(PR Newswire)

November 23, 2022
AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The...(PR Newswire)

November 15, 2022
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is still...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.